Eli Lilly's Biggest Shareholder Is Selling $347 Million of Stock. Should You Sell Too?
Key Points
The sale has nothing to do with the stock's potential, however.
And Lilly remains well positioned to continue winning the GLP-1 race.
- Motley Fool Issues Rare "Total Conviction" Buy Alert ›
The largest shareholder of Eli Lilly (NYSE: LLY) is selling 300,000 shares of the giant drugmaker, which would have a market value of $347 million (at the time of the announced sale).
The question for other Lilly shareholders, then, is, "Should you be selling too?"
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
And the answer is, "Absolutely not." For several reasons.
Not about the stock's growth potential
First, the shareholder in question is the Lilly Foundation, a tax-exempt private foundation established in 1968 and supported by donations from Eli Lilly. It owns about 9.6% of Lilly's outstanding shares, making it the largest shareholder.
And the sale is not being made because that foundation is suddenly bearish on Eli Lilly stock. Instead, it's a required annual charity payout. So, the sale, though rather large, has nothing to do with the stock's potential.
Second, Lilly is currently winning the race to dominate perhaps the biggest revolution in decades in pharmaceuticals. I'm talking about the rapid expansion of GLP-1 drugs. Late last year, Lilly's drug tirzepatide, which it markets as Mounjaro for diabetes and Zepbound for weight loss, became the world's best-selling drug, knocking Merck's cancer drug Keytruda out of the top spot.
Image source: Getty Images.
Morgan Stanley forecasts that the market for GLP-1 drugs will more than double to $190 billion between 2025 and 2035.
Finally, despite the 49% run-up in Lilly's share price over the past year, Wall Street sees additional upside. The average analyst price target for the stock is now $1,328, which is about 10% above the current price.
No, you shouldn't be selling Eli Lilly. You should be buying.
Should you buy stock in Eli Lilly right now?
Before you buy stock in Eli Lilly, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Eli Lilly wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $380,579!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,359,789!*
Now, it’s worth noting Stock Advisor’s total average return is 931% — a market-crushing outperformance compared to 212% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of October 16, 2026.
Matthew Benjamin has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Eli Lilly and Merck. The Motley Fool has a disclosure policy.
Recommended Articles
